Krystal Biotech (KRYS) was granted FDA orphan designation for its treatment of Hailey-Hailey disease, according to a post to the agency’s website.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Earnings Call Highlights Growth and Challenges
- Hold Rating Maintained Amid Mixed Market Performance and Future Pipeline Potential
- Krystal Biotech price target raised to $198 from $166 at Citi
- Krystal Biotech Reports Strong Q3 2025 Performance
- Krystal Biotech’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating